Tromboembolismo pulmonar: avances en diagnóstico, tratamiento y prevención
Pulmonary thromboembolism: advances in diagnosis, treatment and prevention

Diego Bratta Castro

Resumen


El tromboembolismo pulmonar (TEP) es una condición médica grave caracterizada por la obstrucción de las arterias pulmonares por un coágulo sanguíneo, generalmente originado en las venas profundas de las extremidades inferiores. Esta patología representa una causa significativa de morbilidad y mortalidad a nivel mundial. La fisiopatología del TEP involucra una compleja interacción entre factores de coagulación, plaquetas y células inflamatorias. La formación del trombo se inicia con la activación plaquetaria y la cascada de coagulación, potenciada por factores como la estasis venosa y estados de hipercoagulabilidad. El diagnóstico del TEP puede ser desafiante debido a su presentación clínica variable. Los síntomas más comunes incluyen disnea, dolor torácico y taquipnea. Las estrategias diagnósticas actuales, combinan la evaluación clínica, biomarcadores como el dímero D, y técnicas de imagen, siendo la angiografía pulmonar por tomografía computarizada el estándar de oro. El tratamiento se centra en la anticoagulación, con los anticoagulantes orales directos ganando prominencia en los últimos años debido a su eficacia y perfil de seguridad mejorado. En casos severos, pueden ser necesarias terapias de reperfusión como la trombólisis. La prevención del TEP, especialmente en poblaciones de alto riesgo, sigue siendo un área de investigación activa. Estrategias como la tromboprofilaxis en pacientes hospitalizados y la identificación de factores de riesgo individuales son cruciales para reducir la incidencia de esta condición potencialmente mortal. Los avances en la comprensión de la fisiopatología del TEP están abriendo nuevas vías para el desarrollo de terapias dirigidas y estrategias de prevención más efectivas.

Pulmonary thromboembolism (PTE) is a serious medical condition characterized by blockage of the pulmonary arteries by a blood clot, usually originating in the deep veins of the legs. This pathology represents a significant cause of morbidity and mortality worldwide. The pathophysiology of PE involves a complex interaction between coagulation factors, platelets and inflammatory cells. Thrombus formation begins with platelet activation and the coagulation cascade, enhanced by factors such as venous stasis and hypercoagulable states. The diagnosis of PE can be challenging due to its variable clinical presentation. The most common symptoms include dyspnea, chest pain, and tachypnea. Current diagnostic strategies combine clinical evaluation, biomarkers such as D-dimer, and imaging techniques, with computed tomography pulmonary angiography being the gold standard. Treatment focuses on anticoagulation, with direct oral anticoagulants gaining prominence in recent years due to their effectiveness and improved safety profile. In severe cases, reperfusion therapies such as thrombolysis may be necessary. Prevention of PTSD, especially in high-risk populations, remains an area of active research. Strategies such as thromboprophylaxis in hospitalized patients and identification of individual risk factors are crucial to reduce the incidence of this potentially fatal condition. Advances in understanding the pathophysiology of PTSD are opening new avenues for the development of targeted therapies and more effective prevention strategies.

Recibido: 21-05-2024
Aprobado: 02-07-2024
Publicado: 01-11-2024


Palabras clave


hipercoagulabilidad; factores de riesgo; biomarcadores; hypercoagulabilit; risk factors; biomarkers.

Texto completo:

PDF

Referencias


Alias, S., Redwan, B., Panzenböck, A., Winter, M. P., Schubert, U., Voswinckel, R., Frey, M. K., Jakowitsch, J., Alimohammadi, A., Hobohm, L., Mangold, A., Bergmeister, H., Sibilia, M., Wagner, E. F., Mayer, E., Klepetko, W., Hölzenbein, T. J., Preissner, K. T., & Lang, I. M. (2014). Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(4), 810-819.

Avgerinos, E., Bouris, V., & Chaer, R. (2024). Endovascular Treatment of Pulmonary

Embolism. In Mastering Endovascular Techniques: Tips and Tricks in Endovascular Surgery (pp. 803-810). Cham: Springer International Publishing.

Barbar, S., Noventa, F., Rossetto, V., Ferrari, A., Brandolin, B., Perlati, M., De Bon, E., Tormene, D., Pagnan, A., & Prandoni, P. (2010). A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of Thrombosis and Haemostasis, 8(11), 2450-2457.

Barco, S., Mahmoudpour, S. H., Planquette, B., Sanchez, O., Konstantinides, S. V., & Meyer,

G. (2020). Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. European Heart Journal, 41(17), 1771-1780. https://doi.org/10.1093/eurheartj/ehz873

Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., Vazquez, S. R., Greer, I. A., Riva, J. J., Bhatt, M., Schwab, N., Barrett, D., LaHaye, A., & Rochwerg, B. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances, 2(22), 3317-3359.

Becattini, C., Agnelli, G., Lankeit, M., Masotti, L., Pruszczyk, P., Casazza, F., Vanni, S., Nitti,

C., Kamphuisen, P., Vedovati, M. C., De Natale, M. G., & Konstantinides, S. (2019). Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 53(4), 1802094. https://doi.org/10.1183/13993003.02094-2018

Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., Grandone, E., & Prandoni, P. (2012). Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine, 366(21), 1959-1967.

Becattini, C., Vedovati, M. C., & Agnelli, G. (2016). Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation, 116(4), 427-433.

Chapin, J. C., & Hajjar, K. A. (2015). Fibrinolysis and the control of blood coagulation. Blood Reviews, 29(1), 17-24.

Engelmann, B., & Massberg, S. (2013). Thrombosis as an intravascular effector of innate immunity. Nature Reviews Immunology, 13(1), 34-45.

Falanga, A., Russo, L., Milesi, V., and Vignoli, A. (2017). Mechanisms and risk factors of

thrombosis in cancer. Critical Reviews in Oncology/Hematology, 118, 79-83.

https://doi.org/10.1016/j.critrevonc.2017.08.003

Fernandez, C., Bova, C., Sanchez, O., Prandoni, P., Maestre, A., Monreal, M., Patrono, C., Tripodi, A., Lensing, A. W. A., & Jiménez, D. (2020). Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism. Chest, 157(4), 843-851.

Franco-Moreno, A., Muñoz-Rivas, N., Torres-Macho, J., Bustamante-Fermosel, A., Ancos-

Aracil, C. L., y Madroñal-Cerezo, E. (2024). Revisión sistemática de los ensayos clínicos sobre terapia antitrombótica con inhibidores del factor XI. Revista clínica española, 224(3), 167-177.

Godínez, V. A. R., Carrillo, E. R., y Cabello, A. R. (2020). Trampas extracelulares de

neutrófilos en sepsis. Medicina Crítica, 34(2), 156-159. https://doi.org/10.35366/93970

Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012). Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2), e227S-e277S.

Guérin, L., Couturaud, F., Parent, F., Revel, M. P., Gillaizeau, F., Planquette, B., Pontal, D., Guegan, M., Simonneau, G., Meyer, G., & Sanchez, O. (2017). Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thrombosis and Haemostasis, 117(02), 246-255.

Harjola, V. P., Mebazaa, A., Čelutkienė, J., Bettex, D., Bueno, H., Chioncel, O., Crespo-Leiro, M. G., Falk, V., Filippatos, G., Gibbs, S., Leite-Moreira, A., Lassus, J., Masip, J., Mueller, C., Mullens, W., Naeije, R., Nordegraaf, A. V., Parissis, J., Riley, J. P., & Seferovic, P. (2016). Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 18(3), 226-241.

Heit, J. A. (2015). Epidemiology of venous thromboembolism. Nature Reviews Cardiology, 12(8), 464-474.

Heit, J. A., Spencer, F. A., and White, R. H. (2016). The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 41(1), 3-14.

Jiménez-Alcázar, M., Rangaswamy, C., Panda, R., Bitterling, J., Simsek, Y. J., Long, A. T., Bilyy, R., Krenn, V., Renné, C., Renné, T., Kluge, S., Panzer, S., Fuchs, T. A., & Mannherz, H. G. (2017). Host DNases prevent vascular occlusion by neutrophil extracellular traps. Science, 358(6367), 1202-1206.

Karbach, S., Wenzel, P., Waisman, A., Munzel, T., & Daiber, A. (2014). eNOS uncoupling in cardiovascular diseases--the role of oxidative stress and inflammation. Current Pharmaceutical Design, 20(22), 3579-3594.

Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., Stevens, S. M., Vintch, J. R. E., Wells, P., Woller, S. C., & Moores, L. (2016). Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 149(2), 315-352.

Keller, K., Hobohm, L., Ebner, M., Kresoja, K. P., Münzel, T., Konstantinides, S. V., & Lankeit, M. (2020). Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal, 41(4), 522-529.

Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., O'Reilly, E. M., Patel, J. N., Yimer, H. A., Wildgoose, P., Burton, P., Vijapurkar, U., Kaul, S., Eikelboom, J., McBane, R. D., & Weitz, J. I. (2019). Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. New England Journal of Medicine, 380(8), 720-728.

Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 191, 145-147.

Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G. J., Harjola, V. P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., Kucher, N., Lang, I. M., Lankeit, M., Lorusso, R., Mazzolai, L., Meneveau, N., Ní Áinle, F., Prandoni, P., Pruszczyk, P., & Zamorano, J. L. (2020). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 41(4), 543-603.

Koupenova, M., Kehrel, B. E., Corkrey, H. A., & Freedman, J. E. (2017). Thrombosis and platelets: an update. European Heart Journal, 38(11), 785-791.

Kuo, W. T., Banerjee, A., Kim, P. S., DeMarco, F. J., Levy, J. R., Facchini, F. R., Unver, K., Bertini, M. J., Sista, A. K., Hall, M. J., Rosenberg, J. K., & Hofmann, L. V. (2015). Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. Chest, 148(3), 667-673.

Lankhaar, J. W., Westerhof, N., Faes, T. J., Marques, K. M., Marcus, J. T., Postmus, P. E., & Vonk-Noordegraaf, A. (2006). Quantification of right ventricular afterload in patients with and without pulmonary hypertension. American Journal of Physiology-Heart and Circulatory Physiology, 291(4), H1731-H1737.

Le Roux, P. Y., Pelletier-Galarneau, M., De Laroche, R., Hofman, M. S., Zuckier, L. S., Roach, P., Vidal-Sicart, S., & Hicks, R. J. (2015). Pulmonary scintigraphy for the diagnosis of acute pulmonary embolism: a survey of current practices in Australia, Canada, and France. Journal of Nuclear Medicine, 56(8), 1212-1217.

Lobo, J. L., Holley, A., Tapson, V., Moores, L., Oribe, M., Barrón, M., Otero, R., Nauffal, D., Valle, R., Monreal, M., Yusen, R. D., & Jiménez, D. PROTECT and RIETE investigators (2014). Prognostic significance of tricuspid annular displacement in normotensive patients with acute symptomatic pulmonary embolism. Journal of thrombosis and haemostasis, 12(7), 1020–1027. https://doi.org/10.1111/jth.12589

Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020). Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery, 19(5), 333-352.

Meinel, F. G., Nance, J. W., Schoepf, U. J., Hoffmann, V. S., Thierfelder, K. M., Costello, P., Goldhaber, S. Z., & Bamberg, F. (2015). Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. The American Journal of Medicine, 128(7), 747-759.e2.

Meyer, G., Vicaut, E., Danays, T., Agnelli, G., Becattini, C., Beyer-Westendorf, J., Bluhmki, E., Bouvaist, H., Brenner, B., Couturaud, F., Dellas, C., Empen, K., Franca, A., Galiè, N., Geibel, A., Goldhaber, S. Z., Jimenez, D., Kozak, M., Kupatt, C., & Konstantinides, S. V. (2014). Fibrinolysis for patients with intermediate-risk pulmonary embolism. New England Journal of Medicine, 370(15), 1402-1411.

M., Van Kralingen, K. W., & Le Gal, G. (2014). Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 311(11), 1117-1124.

Nosaka, M., Ishida, Y., Kimura, A., Kuninaka, Y., Inui, M., Mukaida, N., & Kondo, T. (2019). Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice. The Journal of Clinical Investigation, 129(1), 279-295.

Owens, A. P., & Mackman, N. (2011). Microparticles in hemostasis and thrombosis. Circulation Research, 108(10), 1284-1297.

Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen,

A. M., Arai, S., Grupp, S. A., Guinan, E. C., Martin, P. L., Steinbach, G., Krishnan, A., Nemecek, E. R., Giralt, S., Rodriguez, T., Duerst, R., Doyle, J., Antin, J. H., Smith, A., ... Soiffer, R. J. (2016). Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 127(13), 1656-1665. https://doi.org/10.1182/blood-2015-10-676924

Righini, M., Van Es, J., Den Exter, P. L., Roy, P. M., Verschuren, F., Ghuysen, A., Rutschmann, O. T., Sanchez, O., Jaffrelot, M., Trinh-Duc, A., Le Gall, C., Moustafa, F., Principe, A., Van Houten, A. A., Ten Wolde, M., Douma, R. A., Hazelaar, G., Erkens, P. M., Van Kralingen, K. W., Grootenboers, M. J., & Le Gal, G. (2014). Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 311(11), 1117–1124. https://doi.org/10.1001/jama.2014.2135

Rodger, M. A., Le Gal, G., Anderson, D. R., Schmidt, J., Pernod, G., Kahn, S. R., Righini, M., Mismetti, P., Kearon, C., Lambert, C., Kelton, J. G., Wells, P. S., Kovacs, M. J., & Meziere, G. (2017). Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ, 356, j1065.

Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013). Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine, 368(8), 709-718.

Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., Lansing, J., Balduzzi, S., Darzi, A., Morgano, G. P., Neumann, I., Nieuwlaat, R., Yepes-Nuñez, J. J., Zhang, Y., & Wiercioch, W. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Advances, 2(22), 3198-3225.

Siordia, J. A., & Kaur, A. (2022). Catheter-directed Thrombolysis versus Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis. Current cardiology reviews, 18(1), 112–117. https://doi.org/10.2174/1573403X17666210603114116

Spyropoulos, A. C., Ageno, W., Albers, G. W., Elliott, C. G., Halperin, J. L., Hiatt, W. R., Maynard, G. A., Steg, P. G., Weitz, J. I., Suh, E., Spiro, T. E., Barnathan, E. S., & Raskob, G. E. (2018). Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. New England Journal of Medicine, 379(12), 1118-1127.

Tapson, V. F., Sterling, K., Jones, N., Elder, M., Tripathy, U., Brower, J., Maholic, R. L.,

Ross, C. B., Natarajan, K., Fong, P., Greenspon, L., Tamaddon, H., Piracha, A. R., Engelhardt, T., Katopodis, J. N., Marques, V., Sharp, A. S., Piazza, G., & Goldhaber, S. Z. (2017). A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. JACC. Cardiovascular Interventions, 10(12), 1149-1158. https://doi.org/10.1016/j.jcin.2017.03.032

Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013). Epidemiology

of cancer-associated venous thrombosis. Blood, 122(10), 1712-1723.

https://doi.org/10.1182/blood-2013-04-460121

Tritschler, T., Kraaijpoel, N., Le Gal, G., and Wells, P. S. (2018). Venous thromboembolism: Advances in diagnosis and treatment. JAMA, 320(15), 1583-1594.

van der Hulle, T., Cheung, W. Y., Kooij, S., Beenen, L. F., van Bemmel, T., van Es, J., Faber, L. M., Hazelaar, G. M., Heringhaus, C., Hofstee, H., Hovens, M. M., Kaasjager, K. A., van Klink, R. C., Kruip, M. J., Loeffen, R. F., Mairuhu, A. T., Middeldorp, S., Nijkeuter, M., van der Pol, L. M., & Klok, F. A. (2017). Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. The Lancet, 390(10091), 289-297.

Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., Prandoni, P., & EINSTEIN CHOICE Investigators (2017). Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. The New England journal of medicine, 376(13), 1211–1222. https://doi.org/10.1056/NEJMoa1700518.

Wolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015). Venous thrombosis. Nature reviews. Disease primers, 1, 15006. https://doi.org/10.1038/nrdp.2015.6

Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., MacCallum, P., Kakkar, A., Hobbs, F. D. R., Petrou, S., Dale, J., Poole, C. J., Maraveyas, A., & Levine, M. (2018). Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20), 2017-2023.

Zagorski, J., Debelak, J., Gellar, M., Watts, J. A., & Kline, J. A. (2003). Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres. The Journal of Immunology, 171(10), 5529-5536.


Enlaces refback

  • No hay ningún enlace refback.


 

Depósito Legal Electrónico: ME2016000090
ISSN Electrónico: 2610-797X

DOI: https://doi.org/10.53766/GICOS

Se encuentra actualmente registrada y aceptada en las siguientes base de datos, directorios e índices: 

 
 
   
    
    
   

Creative Commons License
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.